Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Paige Malick

Physician Assistant Orlando, FL Physician Assistant

NPI 1083213102 CMS profile 11031601

5979 Vineland Rd Ste 310, Orlando, FL 32819

Open in the dashboard

General payments

$4,984

221 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paige Malick of Orlando, FL is reported in the CMS Open Payments database as having received $4,984 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,280 67
2024 General $1,924 82
2023 General $1,569 65
2022 General $212 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paige Malick
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Paige Malick were reported at $1,280. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Paige Malick Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $212 $155 $48–$522 $149
2023 $1,569 $167 $52–$557 $160
2024 $1,924 $178 $55–$600 $164
2025 $1,280 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,069 31 payments
  2. Novo Nordisk Inc $889 47 payments
  3. AbbVie, Inc. $514 24 payments
  4. Lilly USA, LLC $343 13 payments
  5. GlaxoSmithKline, LLC. $330 21 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $256 17 payments
  7. Amgen Inc. $250 8 payments
  8. Otsuka America Pharmaceutical, Inc. $235 12 payments
  9. ITI, Inc. $223 14 payments
  10. Pfizer Inc. $150 8 payments
  11. Other $726 26 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,984 221 payments
Products named General payments · program years 2022–2025
  1. FARXIGA $666 14 payments
  2. Ozempic $623 34 payments
  3. RYBELSUS $578 32 payments
  4. BREZTRI $515 13 payments
  5. AIRSUPRA $460 8 payments
  6. MOUNJARO $305 11 payments
  7. VRAYLAR $303 12 payments
  8. XIFAXAN $256 17 payments
  9. Otezla $250 8 payments
  10. REXULTI $235 12 payments
  11. Other $2,791 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,174

Median for Physician Assistant: 241

Drug cost

$436,211

Median for Physician Assistant: $4,110

Branded share of claims

31.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 89 $96,975
Ozempic Semaglutide Brand 61 $76,214
Janumet Sitagliptin Phos/Metformin Hcl Brand 26 $28,669
Jardiance Empagliflozin Brand 24 $26,214
Eliquis Apixaban Brand 27 $20,144
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $19,489
Trulicity Dulaglutide Brand 20 $19,287
Mounjaro Tirzepatide Brand 16 $18,608
Tresiba Flextouch U-200 Insulin Degludec Brand 25 $17,947
Tradjenta Linagliptin Brand 16 $17,469

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $176
$176 16 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $169
$169 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $157
$157 — —
CAPLYTA
  • ITI, Inc. $150
$150 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $138
$138 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record